Yeon Hee Park, MD, PhD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, presents final updates from the Phase II NOV120101-203 trial (NCT02418689) evaluating poziotinib in patients with HER2-positive metastatic breast cancer, highlighting the potential benefit of this pan-HER tyrosine kinase inhibitor following progression using trastuzumab deruxtecan. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.